YURTDIŞI MAKALE


1-ONAT H, İnceman Ş, Bilge N, Dinçol K, Töre G, Topuz E. Effect of Tamoksifen on Antithrombin III activation in breast cancer.
Proc 15 th Interantional congress of chemotherapy 279-281, 1987.

2-Yasasever V, Bilge N, Töre G, ONAT H, Enginun M. Menstural cycle values of tumor marker in healthy women and in patients with non- gynecological tumors.
Clin Exp Obst Gyn 17 (3-4): 121-129, 1990.

3- ONAT H, Yasasever V, Şengün Z, Dalay N. Osteocalcin: A valuable bone metastasis marker.
Eur J Gynaec Oncol 12(5): 399-402, 1991.

4-Yasasever V, Şengün Z, Saydan N, ONAT H, Dalay N. Serum values of CA 72.4 in patients with gastrointestinal system tumors comparison with CEA and Ca 19.9.
Eur J Gynaec Oncol 13(5): 403-408, 1992.

5- Yasasever V, Karaloğlu D, Yazıcı H, ONAT H, Dalay N. Serum neu oncoprotein levels as a tumor marker in breast cancer.
J Tumor Marker Oncol 7(2): 33-42, 1992.

6-ONAT H, Altun M, Bilge N, Karadeniz A, Ertürk N, Aydıner A, Aykan F. Neoadjuvant chemotherapy and radiotherapy in locally advanced undifferentiated nasopharyngeal carcinoma.
J Exp Clin Res 11(3): 203-206, 1992.

7- ONAT H, İnanç ES, Yasasever V, Dalay N. Effects of cisplatin on erythropoietin and iron changes.
Eur J Can 29A(5): 777, 1993.

8- Aydıner A, ONAT H, Öztürk N, Aykan F, İnanç S, Topuz E, Dinçol K. The efficacy of a five drug antiemetic combination on the consequent cisplatin and cyclophosphamide-doxorubicin containing chemotherapy regimen.
J Pain and Synptom Management 8(3): 126-131, 1993.

9- İnanç ES, ONAT H. Brief weekly chemotherapy for elderly patients with intermediate grade anf high grade on Hodgkin Lymphoma.
J Nat Can Inst 85(13). 1088, 1993.

10- Aykan NF, Bilge N, ONAT H, Kınay M, Topuz E, Dinçol K, Necatioğlu B, Uzal C. Le role de prognostic des transfusions sanguınes dans la maladie de Hodgkin .
Med Bull Istanbul 26: 38-42, 1993.

11-Aydıner A, Olgaç V, Darendeliler E, Öztürk N, Dinçol K, Erseven G, ONAT H. Testicular germ cell tumor with gastric metastasis.
Acta Oncol 32(4): 459, 1993.

12- İnanç Es, Altun M, ONAT H, Erseven G. Sweet's syndrome and Hodgkin's disease
Acta Oncol 33(5): 574-575, 1994.

13-ONAT H, İnanç S, Karaloğlu D, Ertürk N, Dalay N, Yasasever V. Acute coagulation changes during cytotoxic chemotherapy.
J Exp Clin Cancer Res. 13(1): 89-92, 1994.

14- Baltalı E, İçli F, Molinas Mandel N, ONAT H, Aktan G, Ober A, Üskent N, Kınay M, Berk Ö, Fırat D. Neoadjuvant weekly epirubicin chemotherapy of locally advanced breast cancer.
Proc International cancer congress, 1451-1453, 1994.

15- Dinçol D, Mandel N, Barışta I, Aktan G, ONAT H, Sardaş OS, Berk Ö, Çehrelli C, Fırat D. Weekly epirubicin in combination chemotherapyint the treatment of intermediate and high grade non- Hodgkin's lymphoma.
Proc International cancer congress, 2633-2637, 1994.

16- Karaloğlu D, Yazıcı H, Alatlı C, Yaman F, Aslay I, ONAT H, Dalay N. Detection og HPV 16 and HPV 18 infection in patients with cervical neoplasia.
Eur. J. Gynaec. Oncol. 17 (4) 296-298, 1995.

17- ONAT H. Nasopharyngeal cancer.
Recenti progressi nel controllo farmacologico dei tumori 207- 212, 1996.

18- Fırat D, Baltalı E, İçli F, ONAT H, Mandel N, Berk Ö, Ober A, Aktan G. Phase II study of weekly doses of epiubicin in advanced breast cancer.
Turkish J Cancer 26(2): 62- 69, 1996.

19- Berk Ö, ONAT H, Kars A, Serdengeçti S, Günel N, Aykan F, Okkan S, Kınay M, Üskent N, Aktan G, Fırat D. High dose epirubicin and ifosfamide alteranting with etoposide and cisplatin therapy with granulocyte macrophage colony stimulating factor in small cell lung cancer.
Turkish J Cancer 26(3): 119-126, 1996.

20- Kurul S, İnanç S, Darendeliler E, ONAT H, Çakmak M, Topuzlu C, Aslay I, Erseven G. Reconstruction after resection of soft tissue sarcoma of the trunk.
Med. Bull. İstanbul, 29(2): 77- 83, 1996

21- ONAT H, İnanç ES, Saip P, Topuz E. Prevention of chemotherapy induced emesis in patients with germ cell tumors receiving multiple day cisplatin based chemotherapy.
Turkısh J Cancer 26(4): 159-164, 1996.

22- İnanç SE, ONAT H, Oğuz H, Topuz E. Autoimmune phenomena in patients receiving alpha interferon therapy.
Cancer Invest 14(6): 642-643, 1996.

23- Saip P, ONAT H, İnanç SE, Topuz E, Dişçi R. The effect of donzetron and dowpenidon as antiemetics in breast cancer patients receiving cyclophosphamide, epirubicin and fluorouracil during three subsequent courtes.
Turkish J Cancer 27(1): 27-36, 1997.

24- Dinçol D, Molinas NM, Barışta İ, Aktan G, ONAT H, Sardaş OS, Berk Ö, Çehreli C, Fırat D. Combination chemotherapy involving weekly epirubicin in the treatment of intermediate and high grade non-Hodgkin’s lymphomas.
Turkish J Cancer 27(3): 91-97, 1997.

25- Saip P, İnanç SE, ONAT H. Mesna/Ifosfamide, Mitoxamtrone and Etoposide combination chemotherapy in refractory and relapsing non-Hodgkin’s lymphoma.
J BUON 2:145-150, 1998.

26- Saip P, Yasasever V, Tenekeci N, Aydıner A, İnanç S, ONAT H, Dişci R, Topuz E. Prediction of radiological response of bone metastases to therapy by biochemical marker monitoring in patients with breast cancer.
J Tumor Marker Oncol 13(3):45-52, 1998.

27- Yazıcı H, Saip P, İnanç S, ONAT H, Dalay N. Investigation of the molecular changes during chemotherapy in non_hodgkin’s lymphoma.
Research Com Molecular Pathol and Pharmacol 100(3):301-311, 1998.

28- Yazıcı H, Yalçınkaya L, İnanç S, ONAT H, Saip P, Dalay N Bcl-2 gene rearrangements and apoptosis rates in patients with non-Hodgkin’s lymphoma during chemotherapy.
Clin Biochem 32(1):45-49, 1999.

29- İnanç SE, Meral R, Darendeliler E, Yasasever V, ONAT H Prognostic significance of marker half life during chemotherapy in nonseminomatous germ cell testicular tumors.
Acta Oncologica 38(4):505-509, 1999

30- Eralp Y, Bavbek S, Başaran M, Doğan Ö, Çamlıca H, Kaytan E, Darendeliler E, ONAT H Survival and prognostic factors in patients with Hodgkin’s disease
Turkish Hematology-Oncology J 10(3):119-125, 2000

31- Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Eralp L, Özger H, Bilgiç B, Kalaycı G, ONAT H Prognostic factors and survival in patients with metastatic soft tissue sarcoma
J BUON 5:281-286, 2000

31- Eralp Y, Bavbek, S, Başaran M, Kaytan E, Yaman F, Bilgiç B, Darendeliler E, ONAT H Prognostic factors and survival in late adolescent and adult patients with small round cell tumors
Am J Clin Oncol 25(4):418-424, 2002

32- Alici S, Bavbek S, Eralp Y, Argon A, Basaran M, Aydiner A, Tuzlali S, Topuız E, ONAT H An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subcutaneous involvement; report of a case with literature review.
J BUON 7:373-376, 2002

33- Alici S, Bavbek S, Kaytan E, Basaran M, Eralp Y, ONAT H Aggressive Non-Hodgkin’s Lymphoma treated at the Institutew of Oncology, Istanbul
Am J Clin Oncol 25(5):502-508, 2002

34- Basaran M, Bavbek S, Güllü İ, Demirelli F, ONAT H A phase II study of Paclitaxel and Cisplatin combination chemotherapy in recurrent or metastatic Head and Neck cancer
J Chemotherapy 14(2):207-213, 2002

35- ONAT H, Başaran M, Esassolak M, Bavbek S, Anacak, Y, Kaytan E, Altun M, Haydaroğlu High dose Epirubicin and Cisplatin in locally advanced undifferentiated nasopharyngeal caecinoma
Clin Oncol 14(6):449-454, 2002

36- Alıcı S, Bavbek ES, Kaytan E, Eralp Y, ONAT H Prognodtic factors in localized Aggressive Non-Hodgkin’s Lymphoma
A J Clin Oncol 26(1):1-5, 2003

37- Alici S, Bavbek ES, Kaytan E, Başaran M, Bulutlar G, ONAT H Survival outcomes in aggressive non-Hodgkin’s lymphoma according to the International Prognostic Index
J BUON 8:121-126, 2003

38- Baujat, B, Audry H,Bourhis J, Chan ATC, ONAT, H, Chua DTT, Kwong DLW, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP (The MAC-NPC Collaborative Group). Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-anlaysis of eight randomized trials and 1753 patients
In t J Radiation Biol Phys 64(1):47-56, 2006

39- Alıcı S, Bavbek S, Başaran M, ONAT H "Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first line therapy"
Adv Therapy 23(4):534-542, 2006